L-Theanine
L-Theanine produces an 'alert-calm' state, validated by alpha-EEG (Nobre 2008) and four independent caffeine-stack RCTs (Owen 2008, Kelly 2008, Giesbrecht 2010, Haskell 2008) at the canonical 200 mg theanine + 100 mg caffeine ratio. Hidese 2019 systematic review confirms anxiolytic effect (SMD ~0.3-0.5) at 200-400 mg single dose with 30-60 min onset.
L-Theanine scored 7.5 / 10 (💪 Strong recommend) on the BioHarmony scale as a Substance → Amino Acid.
What It Is
Type: Amino acid analog (glutamate-derived; non-proteinogenic; from Camellia sinensis tea leaf).
Current status: Actively using.
L-Theanine is the non-proteinogenic amino acid that gives green tea its calming counterpoint to caffeine's stimulation. Once across the blood-brain barrier, it modulates glutamate receptors (NMDA antagonism, AMPA modulation) and increases GABA, serotonin, and dopamine, while enhancing alpha-wave EEG activity, the brain state of relaxed attention. The signature use case is the "alert-calm" produced by stacking 200 mg theanine with 100 mg caffeine, validated across at least four independent RCTs. It is among the safest, cheapest, fastest-acting nootropics available.
Terminology
- Suntheanine: Branded pure L-theanine from Taiyo International; >99% L-isomer.
- Alpha waves: 8-13 Hz EEG activity associated with relaxed attention; characteristic meditation brainwave.
- GABA: Gamma-aminobutyric acid, the brain's primary inhibitory neurotransmitter.
- NMDA / AMPA: Glutamate receptor subtypes; theanine modulates both.
- Cohen's d / SMD: Standardized mean difference, effect-size metric. d 0.3-0.5 = small-moderate.
- GRAS: FDA's 'Generally Recognized as Safe' designation.
How this score is calculated →
Upside (3.36 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 3.2 | 0.800 | |
| Breadth of Benefits | 15% | 3.5 | 0.525 | |
| Evidence Quality | 25% | 3.8 | 0.950 | |
| Speed of Onset | 10% | 4.0 | 0.400 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality Upside | 15% | 3.2 | 0.480 | |
| Total | 3.355 |
Upside Rationale
Efficacy (3.2/5.0) . Acute anxiolytic effect SMD ~0.3-0.5 at 200-400 mg (Hidese 2019, PMID 31623400, systematic review). Caffeine-stack synergy on working memory and reaction time replicated across four independent RCTs (Owen 2008 PMID 18681988, Kelly 2008, Giesbrecht 2010, Haskell 2008). Anxious-baseline responders see ~2x effect vs calm-baseline users. Effect sizes are small-to-moderate, not transformative . But reliable.
Breadth of benefits (3.5/5.0) . Anxiety, stress, sleep onset, cognition, focus, BP/HR under stress, mood adjunct, schizophrenia adjunct (Ritsner 2011 PMID 21208586). Multi-system impact via central GABA/glutamate modulation, even if modest in any single domain.
Evidence quality (3.8/5.0) . Multiple RCTs across endpoints, Hidese 2019 systematic review, direct neurophysiological evidence (Nobre 2008 PMID 18296328 alpha-EEG). Some industry funding from Suntheanine manufacturer (Taiyo) but caffeine-stack RCTs include independent academic replication. Apply −0.3 industry adjustment, +0.2 for replication = net 3.8.
Speed of onset (4.0/5.0) . Anxiolytic in 30-60 min; alpha-EEG response 30-45 min. Among the fastest-acting evidence-backed nootropics. Stack effect with caffeine peaks within an hour.
Durability (2.0/5.0) . 4-8 hour acute window; no carryover; no tolerance accumulation; effect requires re-dosing. The flip side of safety: every effect resets.
Bioindividuality (3.2/5.0) . Anxious-baseline responders get the strongest effect. Calm-baseline users frequently report "felt nothing." Roughly 60-70% of users get a meaningful response. No clear genetic predictors.
Downside (1.69 / 5.00)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.3 | 0.390 | |
| Side Effect Profile | 15% | 1.4 | 0.210 | |
| Financial Cost | 5% | 1.2 | 0.060 | |
| Time/Effort Burden | 5% | 1.1 | 0.055 | |
| Opportunity Cost | 5% | 1.3 | 0.065 | |
| Dependency / Withdrawal | 15% | 1.5 | 0.225 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.255 | |||
| Harm subtotal × 1.4 | 1.505 | |||
| Opportunity subtotal × 1.0 | 0.180 | |||
| Combined downside | 1.685 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.345 |
Downside Rationale
Safety risk (1.3/5.0) . FDA GRAS (GRN 209, 2007); EFSA acceptable at 200-400 mg/dose; Japanese food-additive history since the 1960s. No SAEs, no FAERS signal, no catastrophic risk floor trigger. Among the safest supplements available.
Side effect profile (1.4/5.0) . Rare and mild: occasional headache, GI upset, unwanted drowsiness at high daytime doses. Mood blunting at sustained 400-600 mg/day reported in a small minority.
Financial cost (1.2/5.0) . $0.10-0.25 per 200 mg dose. Generic Suntheanine in bulk is among the cheapest evidence-backed nootropics.
Time/effort burden (1.1/5.0) . Swallow a capsule. Trivial.
Opportunity cost (1.3/5.0) . Minimal. Stacks well with everything; doesn't displace other interventions; could trigger laziness about fixing root causes of anxiety, but that's a personal-discipline issue, not the molecule's fault.
Dependency / withdrawal (1.5/5.0) . No physiological dependency, no rebound, no tolerance. Theoretical GABA-A adaptation has not surfaced in any clinical literature.
Reversibility (1.0/5.0) . Fully reversible. Effect ends within 4-8 hours; no residual changes.
Verdict
✅ Best for: Anyone stacking caffeine or stimulants who wants alert-calm instead of jitters; stress-prone individuals before public speaking, presentations, or sleep onset; meditators looking to deepen the practice; users who tolerate prescription anxiolytics poorly; people building a sleep stack who want non-sedating support.
❌ Avoid if: You have severe hypotension or are on multiple antihypertensives (theanine can be additive), you're pregnant/lactating without provider guidance, or you're already using sedatives/benzos/alcohol heavily (compounded sedation). Also skip if you're trying to feel maximum stimulant effect . Theanine deliberately blunts the edge.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| 💪 Cognition / Focus Primary | 7.5 | Caffeine-stack synergy: Owen 2008 PMID 18681988, Kelly 2008, Giesbrecht 2010, Haskell 2008 . Replicated working memory and reaction time gains. |
| 💪 Stress / Resilience Primary | 7.0 | Acute cortisol/HR/BP attenuation under stress challenge; multiple small RCTs. |
| 👍 Sleep Quality Primary | 6.5 | Lyon 2011 PMID 22214254 ADHD pediatric; Williams 2020. Improves subjective sleep without sedation hangover. |
| 💪 Anxiety Primary | 7.5 | Hidese 2019 systematic review SMD ~0.3-0.5; Lopes 2017, Sarris 2019 schizophrenia adjunct (Ritsner 2011 PMID 21208586). Reliable acute anxiolytic at 200-400 mg. |
| 👍 Flow State / Peak Mental Performance | 6.5 | Alpha-wave EEG (Nobre 2008 PMID 18296328) supports relaxed-attention state. |
| 👍 Reaction Time / Coordination | 6.0 | Caffeine stack reduces reaction time relative to caffeine alone (Owen 2008). |
| ⚖️ Mood / Emotional Regulation | 5.5 | Modest mood lift via dopamine/serotonin modulation; Williams 2020 schizophrenia adjunct relevant. |
| ⚖️ HRV / Vagal Tone / Autonomic Balance | 5.5 | BP/HR attenuation under stress translates to modest HRV improvement. |
| ⚖️ Sleep Architecture (Deep/REM) | 5.0 | Modest deep-sleep effects; less robust than mag glycinate or apigenin. |
| ⚖️ Memory | 5.0 | Working-memory gains in caffeine stack; standalone effect modest. |
| ⚖️ Geriatric / Aging Population | 5.0 | Anxiety and sleep applications relevant; clean safety. |
| ○ Depression | 4.0 | Adjunct only; no monotherapy efficacy. |
| ○ Cardiovascular | 4.0 | Acute BP reduction under stress; not a standalone CV intervention. |
| ○ Pediatric Use | 4.0 | Lyon 2011 ADHD pediatric supports use; consult provider. |
| ○ Creativity / Divergent Thinking | 4.0 | Anecdotal flow-state reports; alpha-wave correlation. |
| ○ Spiritual / Consciousness Expansion | 4.0 | Meditation deepening reports; alpha-wave correlation. |
| ○ Neuroprotection | 3.5 | Mechanistic NMDA/glutamate modulation; thin clinical evidence. |
| ○ Energy / Fatigue | 3.0 | Indirect via caffeine optimization; not a primary energetic effect. |
| ○ Healthspan | 3.0 | Indirect via stress and sleep optimization. |
| ○ Neuroplasticity | 3.0 | Animal evidence for BDNF; thin human data. |
| ○ Social Bonding / Empathy | 3.0 | Indirect via social anxiety reduction. |
Frequently Asked Questions
What does L-theanine actually do?
L-theanine produces a calm-but-alert state by crossing the blood-brain barrier and increasing GABA, serotonin, and dopamine while enhancing alpha-wave brain activity (Nobre 2008, PMID 18296328). Functionally, it takes the edge off stimulants like caffeine without sedation. The Hidese 2019 systematic review confirmed reliable anxiolytic effects (SMD ~0.3-0.5) at 200-400 mg. Onset is 30-60 minutes, duration 4-8 hours, with no carryover or dependency.
What's the right L-theanine dose?
Most clinical studies use 200 mg per dose, with 400 mg for stronger anxiolytic or sleep applications. Maximum studied dose is 900 mg/day. The canonical caffeine stack is 200 mg theanine + 100 mg caffeine (2:1 ratio); for sleep, 200-400 mg pre-bed. Higher doses don't appear to add benefit and may produce drowsiness. Take with or without food; absorption is fast either way.
Why pair L-theanine with caffeine?
Four independent RCTs (Owen 2008 PMID 18681988, Kelly 2008, Giesbrecht 2010, Haskell 2008) show that 200 mg theanine + 100 mg caffeine improves working memory and reaction time more than caffeine alone, while attenuating the jitter and BP elevation. This 'alert-calm' effect is the most replicated use case in the L-theanine literature. The natural co-occurrence in tea is the evolutionary template.
Suntheanine vs generic L-theanine . Does it matter?
Yes. Only the L-isomer is bioactive. Suntheanine is pure (>99%) L-theanine; generic supplements are often racemic mixtures with reduced effective dose. Per gram, generic may deliver only half the active L-isomer. Brands carrying the Suntheanine logo (Sports Research, NOW Suntheanine, Jarrow, Doctor's Best) are the safe pick. Cost difference is small.
Is L-theanine safe long-term?
Exceptionally safe. FDA GRAS since 2007 (GRN 209), EFSA acceptable at 200-400 mg/dose, Japanese food-additive history since the 1960s. RCTs out to 12 months in psychiatric adjunct settings show no signal. Side effects are rare: mild headache, GI upset, or unwanted drowsiness at high daytime doses. No tolerance, no dependency, no withdrawal. Tea has delivered theanine to humans at population scale for centuries.
Does L-theanine actually help sleep?
Modest yes. Lyon 2011 (PMID 22214254) showed sleep improvement in pediatric ADHD; Williams 2020 confirmed similar adult signal. The mechanism is anxiolytic rather than sedating . It lowers the activation that prevents sleep onset rather than knocking you out. The Huberman sleep stack (200-400 mg theanine + 145 mg magnesium threonate + 50 mg apigenin) leverages this. Better as part of a sleep stack than as monotherapy.
Can L-theanine deepen meditation?
Plausibly yes. Nobre 2008 (PMID 18296328) directly measured alpha-wave EEG increase 30-45 minutes after a 200 mg dose. Alpha activity is the brain state associated with relaxed attention, the same state experienced practitioners describe in meditation. The acute window (4-8 hours) lines up well with a sit. Anecdotal reports across the meditation community are consistent. No formal meditation-quality RCTs exist.
Who shouldn't take L-theanine?
Very few absolute contraindications. Pregnancy and lactation: insufficient data, treat as relative caution (tea-level intake considered safe). Severe hypotension or use of antihypertensives: theanine may potentiate BP reduction at high doses. Use with sedatives (benzos, alcohol, opioids) is additive . Pleasant for some, oversedating for others. No CYP interactions of clinical significance. People who already feel calm/sluggish may notice nothing.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimension Changes | New Score |
|---|---|---|
| Larger RCT confirms cognition stack benefit beyond caffeine, standalone | Efficacy 3.2→3.8, Evidence 3.8→4.2 | 8.0 / 10 ✅ Top-tier |
| Independent meta-analysis finds anxiolytic effect smaller than Hidese estimate | Efficacy 3.2→2.5, Evidence 3.8→3.5 | 6.7 / 10 👍 Worth trying |
| Robust meditation/flow-state RCT confirms alpha-wave benefit translates to subjective deepening | Efficacy 3.2→3.7, Breadth 3.5→4.0 | 7.9 / 10 💪 Strong recommend |
| Long-term tolerance signal emerges in chronic users | Durability 2.0→1.5, Dependency 1.5→2.5 | 7.1 / 10 💪 Strong recommend |
Key Evidence Sources
- Owen GN et al. (2008) — caffeine + theanine working memory and reaction time. Anchor caffeine-stack RCT
- Nobre AC et al. (2008) — alpha-wave EEG response to 200 mg theanine. Direct neurophysiological evidence for relaxed-attention state
- Hidese S et al. (2019) — systematic review on stress and anxiety. Most current systematic review
- Lyon MR et al. (2011) — pediatric ADHD sleep improvement. Pediatric sleep RCT
- Ritsner MS et al. (2011) — schizophrenia adjunct. Psychiatric adjunct evidence
- Kelly SP et al. (2008) — caffeine + theanine attention task replication. Independent replication of caffeine stack
- FDA GRAS Notice 209 (2007) — Suntheanine GRAS. Regulatory safety basis
- Sarris J et al. (2019) — anxiety meta-analysis update. Meta-analytic confirmation
- Williams JL et al. (2020) — schizophrenia adjunct trial. Adjunct evidence
- Camfield DA et al. (2014) — cognition meta-analysis. Cognition meta-analysis
Other interventions for Cognition & Focus
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. 5.0 is neutral (benefits and risks balance). Above 5 = benefits outweigh risks; below 5 = risks outweigh benefits.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 3.360 − 1.690 = 1.670
EV ranges from −5 to +5. Adding 7 shifts to 2–12, dividing by 12 normalizes to 0–1, then ×10 gives the 0–10 score.
Score = ((1.670 + 7) / 12) × 10 = 7.5 / 10
